Brainstorm Cell Therapeutics Inc (STU:GHD)

€ 2.979 0 (0%) Market Cap: 11.32 Mil Enterprise Value: 11.96 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q2 2024 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Aug 14, 2024

€4.09 (-4.89%)

Earnings
Brainstorm Cell Therapeutics Inc Annual Shareholders Meeting Transcript
Dec 18, 2023
Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Nov 14, 2023

€2.61 (+2.96%)

Earnings
Brainstorm Cell Therapeutics Inc Investor Call Transcript
Oct 18, 2023
Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Aug 14, 2023

€21.9

Earnings
Q1 2023 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
May 15, 2023

€37.2 (-4.62%)

Earnings
Q4 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Mar 30, 2023

€32.62 (+29.31%)

Earnings
Brainstorm Cell Therapeutics Inc To Discuss The Company's Biologics License Application (BLA) for NurOwn(®) Transcript
Mar 27, 2023
Brainstorm Cell Therapeutics Inc Annual Shareholders Meeting Transcript
Jan 10, 2023
Brainstorm Cell Therapeutics Inc at EBD Group Biotech Showcase Transcript
Jan 09, 2023
Q3 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

€22.19 (-8.13%)

Earnings
Brainstorm Cell Therapeutics Inc ALS One Research Symposium Transcript
Oct 07, 2022
Q2 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Aug 15, 2022

€50.19 (+9.42%)

Earnings
Q1 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
May 16, 2022

€38.26 (-1.01%)

Earnings
Q4 2021 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Mar 28, 2022

€45.6 (-2.56%)

Earnings
Q3 2021 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Nov 15, 2021

€39.6 (+2.33%)

Earnings
Brainstorm Cell Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 12, 2021
Q2 2021 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

€49.5 (+4.43%)

Earnings
Q1 2021 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Apr 26, 2021

€41.7 (+2.21%)

Earnings
Q4 2020 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Feb 04, 2021

€83.25 (+9.90%)

Earnings
Brainstorm Cell Therapeutics Inc to Present at the Alliance for Regenerative Medicine Transcript
Jan 08, 2021
Q3 2020 Brainstorm Cell Therapeutics Inc Earnings and Corporate Update Call Transcript
Oct 15, 2020
Brainstorm Cell Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 12, 2020
Q2 2020 Brainstorm Cell Therapeutics Inc Earnings and Corporate Update Call Transcript
Aug 05, 2020
Q1 2020 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
May 07, 2020

€81.75 (-15.50%)

Earnings
Q4 2019 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Feb 18, 2020

€78.75 (+12.66%)

Earnings
Brainstorm Cell Therapeutics Inc at Noble Financial Emerging Growth Investor Conference Transcript
Feb 17, 2020
Brainstorm Cell Therapeutics Inc at 3rd Annual NIF Forum Transcript
Jan 17, 2020
Brainstorm Cell Therapeutics Inc looks forward to top-line results for its ALS Phase 3 program Transcript
Jan 15, 2020
Brainstorm Cell Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum Transcript
Jan 12, 2020

Q1 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

May 16, 2022 / 12:00PM GMT

Release Date Price: €38.26 (-1.01%)

Transcript 10-Q8-K

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics first-quarter 2022 conference call. (Operator Instructions) As a reminder, this call is being recorded. And I would now like to introduce your host for today's conference, Tom Galassi of LifeSci Advisors. Mr. Galassi, you may begin.

Tom Galassi

LifeSci Advisors - IR

Good morning, and thank you for joining us. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts and projections regarding Brainstorm Cell Therapeutics and its potential future operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness for the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.